Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amlodipine + losartan + ezetimibe + rosuvastatin
- Development stage
- Phase 3
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amlodipine + losartan + ezetimibe + rosuvastatin is a fixed-dose combination drug comprised of four small-molecule agents: amlodipine (a calcium channel blocker), losartan (an angiotensin II receptor blocker), rosuvastatin (an HMG-CoA reductase inhibitor/statin), and ezetimibe (a cholesterol absorption inhibitor). This combination targets both hypertension and dyslipidemia, offering concurrent blood pressure reduction and improved lipid profile by lowering LDL cholesterol. Clinical studies demonstrate its efficacy in reducing both systolic blood pressure and LDL-C versus dual- or triple-component comparators, with a safety profile comparable to the use of individual agents. The single-pill combination is intended to enhance treatment adherence in patients requiring simultaneous management of both hypertension and dyslipidemia[1][2][3][5].
- Brand names
- Amosartan XQ
- Other names
- amlodipine/ezetimibe/losartan/rosuvastatinHCP 1701HCP1701HCP-1701Amosartan XQ
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on amlodipine + losartan + ezetimibe + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amlodipine + losartan + ezetimibe + rosuvastatin.